You are here: Home > Results > Grants Funded

Grants Funded

Since 2008, support from Good Cookies like YOU has helped Cookies for Kids' Cancer fund nearly 6 DOZEN childhood cancer research grants, leading to 11 promising new treatments now in clinical trial, available to children fighting cancer TODAY.

Treatments Now in Clinical Trial:

Memorial Sloan-Kettering Cancer Center

HU3F8 antibody treatment

Saponin adjuvant for GD2 conjugate vaccine

Convection-enhanced delivery of 124I-8H9 Brainstem glioma

Children's Hospital of Philadelphia

Engineered t cell therapy - recurrent neuroblastoma & b cell malignancies

Phase I trial of MK1775, approved and activated for accrual

Texas Children's Cancer Center

Phase I/II trials of ABT-888 plus XRT - pediatric brain tumors

Immunotherapy with dual-specific NKT cells - Neuroblastoma

St. Jude Children's Research Hospital

CD-20 targeted therapy - Leukemia

Anti-GD2 monoclonal antibody therapy - Neuroblastoma

Dana-Farber Cancer Institute

Targeting of Cdk4 signaling in pediatric Rhabdoid tumors

Phase II study of clofarabine in refractory Langerhans cell histiocytosis


As of 2013, a portion of funds raised are also used to MATCH, dollar for dollar, the federal allowance per child enrolled in the Children's Oncology Group's Phase I & Pilot Consortium.

COG Phase 1/Pilot Consortium Studies:

A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), a Replication-Competent Picornavirus, in Pediatric Patients with Recurrent/Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors with Neuroendocrine Features

A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma

A Phase 1 Study of Temsirolimus in Combination with Irinotecan and Temozolomide in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors

A Phase 1 Study of JAK Inhibition (Ruxolitinib) in Children with Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms

A Phase I Dose Escalation Study of REOLYSIN, a Replication Competent Reovirus, in Pediatric Patients with Relapsed or Refractory Solid Tumors

A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ 197, IND#112603) in Children with Relapsed or Refractory Solid Tumors

A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children with Refractory or Recurrent Solid Tumors and Lymphoma

A Phase 1 Study of Temsirolimus (CCI-779, IND#61010) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma

A Phase 1 study of AMG 386 (trebananib, IND#114215), an Angiopoietin Neutralizing Peptibody, in Children with Relapsed or Refractory Solid Tumors, including CNS Tumors.

A Phase 1 study of XL184 (Cabozantinib, IND# 116059) in Children and Adolescents with Recurrent or Refractory Solid Tumors, including CNS Tumors

A Phase 1 Study of Crizotinib (IND# 105573) in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

A Phase 1 study of the TEM-1 antibody, MORAb-004 (IND# 103821), in Children with Recurrent or Refractory Solid Tumors

A Phase 1 Study of AZD1775 (MK-1775, IND#116459) Concurrent with Local Radiation Therapy for the Treatment of Newly Diagnosed Children with Diffuse Intrinsic Pontine Gliomas

A Phase 1/2 Study of MK-1775 (AZD1775, IND# 121422) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors

A Phase 1/2 Study of BMN 673 (IND #121510), an Oral Poly(ADP-ribose) Polymerase Inhibitor, Plus Temozolomide in Children with Refractory or Recurrent Malignancies

A Phase 1/2 Trial of Brentuximab Vedotin (SGN35, IND#117117) in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma


Research Grants Funded to Date:

AMOUNT CENTER RESEARCHER GRANT

2014

$100,000

Children's Hospital of Philadelphia

Dr. Maris

Identifying novel drug combinations for neuroblastoma

$100,000

Children's Hospital of Philadelphia

Dr. Aplenc

Chimeric antigen receptor T cell immunotherapy for pediatric acute myeloid leukemia

$150,000*

Children's Oncology Group

Dr. LaQuaglia

Comprehensive national study to standardize treatments after pulmonary metastectomy in patients with newly diagnosed or recurrent osteosarcoma and pulmonary metastasis. *Second year of 3-year project totaling $450,000.

$100,000

Dana-Farber Cancer Institute

Dr. Dranoff

A Phase I Study of irradiated GM-CSF secreting autologous neuroblastoma cell vaccine (GVAX) for relapsed or refractory neuroblastoma

$200,000

Memorial Sloan Kettering Cancer Center

Dr. Modak

Targeting pediatric solid tumors: A pilot study of Radiolmmuno-PET imaging using 124I-Humanized 3F8

$100,000

Memorial Sloan Kettering Cancer Center

Dr. Kushner

Bivalent vaccine plus beta-glucan for high-risk neuroblastoma in first remission

$100,000

St. Jude Children's Research Hospital

Dr. Mullighan

Identifying novel drivers and childhood acute lymphoblastic leukemia disease and resistance

$100,000

Texas Children's Cancer Center

Dr. Zage

A Phase I Study of vandetanib (CaprelsaTM) in combination with 13-cis-retinoic acid in children with relapsed or refractory solid tumors

$100,000

Texas Children's Cancer Center

Dr. Gottschalk

IL13Ra2-CAR T-cell therapy for pediatric high grade glioma

2013

$100,000

Children's Hospital Of Philadelphia

Dr. Nichols

Novel cell-based therapy for b cell leukemias and lymphomas

$100,000

Children's Hospital Of Philadelphia

Dr. Thomas-Tikhonenko

Decreasing resistance to chemotherapies in pediatric lymphomas, and decreasing sensitivities and effects related to the chemotherapy drug Doxorubicin

$350,000

Children's Oncology Group

Matching federal funds per child enrolled in Phase I clinical trials

$150,000*

Children's Oncology Group

Dr. LaQuaglia

Comprehensive national study to standardize treatments after pulmonary metastectomy in patients with newly diagnosed or recurrent osteosarcoma and pulmonary metastasis. *First year of 3-year project totaling $450,000.

$100,000

Dana-Farber Cancer Institute

Dr. Stegmaier

New treatments for neuroblastoma by targeting the Epigenome

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

Retargeting t cells using bispecific antibody against receptor Tyrosine Kinase-like orphan receptors 2 (Ror2) in solid tumors

$100,000

St. Jude Children's Research Hospital

Dr. Inaba

Genetic characterization and therapeutic targeting of pediatric mixed phenotype acute leukemia

$100,000

Texas Children's Cancer Center

Dr. Berg

Phase I trial of Sgt-53, a novel nanoparticle therapy, for children with refractory or recurrent solid tumors

$100,000

Texas Children's Cancer Center

Dr. Metelitsa

Phase I clinical trial of a novel immune therapy using dual-specific Nkt cells for children with neuroblastoma

2012

$350,000

Children's Oncology Group

Matching federal funds per child enrolled in Phase I clinical trials

$100,000

Children's Hospital Of Philadelphia

Dr. Attiyeh

Xpo1 Inhibition in neuroblastoma

$100,000

Children's Hospital Of Philadelphia

Dr. Bassing

Targeting Bcl11b Haploin sufficient lymphoid tumors 6

$100,000

Dana-Farber Cancer Institute

Dr. Roberts

Targeting of Cdk4 signaling in pediatric Rhabdoid tumors

$100,000

Dana-Farber Cancer Institute

Dr. Galiando

Phase II study of clofarabine in refractory Langerhans cell histiocytosis

$100,000

Dana-Farber Cancer Institute

Dr. Shusterman

Csf producing whole tumor vaccine for neurblastoma

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

Dual specific human monoclonal antibody targeting IGF-I and IGF-II for pediatric cancers

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Kramer

Delivery of 124-I-8h9 non-progressive diffuse Pontine Gliomas.

$100,000

St. Jude Children's Research Hospital

Dr. Furman

Hu14.18322a + Multi-Modality treatment for neuroblastoma

$100,000

Texas Children's Cancer Center

Dr. Gottschalk

Fap-targeted t cell therapy for osteosarcoma

2011

$100,000

St. Jude Children's Research Hospital

Dr. Gilbertson

Rapid and accurate diagnosis of Medolloblastoma subtypes in trials

$100,000

Children's Hospital Of Philadelphia

Dr. Maris

Molecular oncology for pediatric cancers

$100,000

Children's Hospital Of Philadelphia

Dr. Weiss

Modeling juvenile myelomonocytic Leukemia patient Ips cells

$100,000

Dana-Farber Cancer Institute

Dr. Stegmaier

Validation of fak therapeutic target in Ewings Sarcoma

$100,000

Dana-Farber Cancer Institute

Dr. George

Development of dendritic call vaccine against Alk-Positive

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

A safe, potent Saponin adjuvant for Gd2 conjugated vaccine for neuroblastoma

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. LaQuaglia

Phase I trial of Hepatic Artery Infusion/neuroblastoma tumors in the liver

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

Bite Therapy

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

Bite Therapy

$100,000

Texas Children's Cancer Center

Dr. Metelitsa

Immunotherapy of neuroblastoma with dual-specific Nkt cells

$100,000

Texas Children's Cancer Center

Dr. Nuchtern

Genomic anatomy of chemotherapy-resistant neuroblastoma

2010

$100,000

Children's Hospital Of Philadelphia

Dr. Grupp

Engineered T Cell Therapy For Recurrent Neuroblastoma & B Cell Malignancies

$100,000

Children's Hospital Of Philadelphia

Dr. Hogarty

Sirna based Kimome screen to id Mcl1 antagonists for resistant Tumors

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

Bite Therapy, 2nd round of funding

$100,000

St Jude Children's Research Hospital

Dr. Bhojwani

CD-20 targeted immunotherapy for relapsed childhood neuroblastoma

$100,000

Texas Children's Cancer Center

Dr. Shohet

Therapy for relapsed neuroblastoma. P13k/Aktm tor pathway inhibition

$100,000

Texas Children's Cancer Center

Dr. Su

Therapy efficacy study for newly diagnosed brainstem gliomas

2009

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

Bite Therapy

$35,000

Texas Children's Cancer Center

Dr. Rabin

Novel therapy using JAK-STAT pathway inhibitors in childhood leukemias

$50,000

Texas Children's Cancer Center

Dr. Louis

A phase I/II study using allogenic tumor cell vaccination with oral metronomic cytoxan in patients with high-risk neuroblastoma

$150,000

Texas Children's Cancer Center

Two Grants

2008

$400,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

Hu3f8 antibody treatment for neuroblastoma